A fresh licensing deal tidies up years of work between the two companies.
ApexOnco Front Page
Recent articles
And that could affect the drug's third-line accelerated approval.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
The company will start three phase 3 trials of its G12D project this year.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
The company secures funding to push its lead candidate towards US approval.
